Zavain Dar is a venture capital investor at Dimension who combines deep technical knowledge in software, AI, and biology to invest in "techbio" companies building foundation models for molecular interactions, with founders describing him as "natively bilingual" between machine learning and life sciences. He runs a concentrated investing approach with roughly 20 positions per fund and often leads sizeable checks so that he and Dimension can work closely with founders as "core architects," rather than holding many small, passive stakes.

• Fascination with the convergence of artificial intelligence and physical sciences, particularly in biology and drug development. A primary investment thesis involves backing companies that use advanced computational models to tackle real world problems like disease treatment. For example, pointing out how Chai Discovery evolved from a small team in their office to partnering with major pharmaceutical companies to accelerate drug discovery, or highlighting Achira for building foundational models focused on the physical and atomistic world.
• Focus on the underlying infrastructure and economic realities of artificial intelligence scaling. There is deep attention paid to hardware bottlenecks, chip costs, and the foundational engineering required to support global artificial intelligence rollout. An example is the recommendation to study theoretical computer science to better understand the future cost curves of advanced compute hardware and the limitations of current scaling laws.
• Appreciation for the unique risk appetite and talent density of the San Francisco Bay Area. The ecosystem is viewed as a historically significant hub that aggregates the smartest minds to tackle frontier challenges. For instance, highlighting how a tight geographic radius contains both startups pushing toward artificial general intelligence and ambitious biotech companies seeking to cure deadly diseases despite operating at a loss.
• Commitment to high conviction and stage agnostic investing across deep tech and science. The strategy involves deploying large amounts of capital into a very concentrated number of companies, often ignoring broader market trends or skepticism if the underlying science is sound. A great example shared is how a partner underwrote the science and pipeline of a therapeutic company right after a failed public offering attempt, purely based on technological merit rather than following negative investor sentiment.
• Belief in the fundamental disruption of traditional business and economic models due to advanced computing. There is a strong view that old playbooks for software valuation are becoming obsolete as artificial intelligence capabilities expand. An example given is how the marginal value of spending capital on artificial intelligence systems is consistently growing compared to spending on human labor, which breaks historical assumptions about terminal value in mainstream businesses.